PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32913546-12 2020 Budesonide treatment also resulted in increased HDAC2 expression and decreased IL-8 and VEGF expression. Budesonide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 79-83 29649811-11 2018 Moreover, budesonide decreased CDK9 phosphorylation and markedly inhibited IL-17F-induced IL-8 production. Budesonide 10-20 C-X-C motif chemokine ligand 8 Homo sapiens 90-94 29127842-8 2018 Dynamic compliance was significantly improved in the budesonide group on days 3 (p=0.018) and 5 (p=0.011) The levels of CXCL-8 and IL-6 diminished on days 3-5 after start of budesonide (p<0.05). Budesonide 53-63 C-X-C motif chemokine ligand 8 Homo sapiens 120-126 29127842-9 2018 CONCLUSION: In COPD patients on MV, nebulized budesonide was associated with reduced BAL CXCL8 and IL-6 levels and neutrophil numbers as well as an improvement in ventilatory mechanics and facilitated weaning. Budesonide 46-56 C-X-C motif chemokine ligand 8 Homo sapiens 89-94 31636329-7 2019 Budesonide strongly suppressed the production of neutrophil attractant CXCL8, and promoted epithelial integrity in A549 wild-type cells, while A549 Rho-0 cells displayed reduced corticosteroid sensitivity compared to wild-type cells. Budesonide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 71-76 27281349-5 2016 Budesonide suppressed secreted chemokines IL-8 and CCL2 (MCP-1) within 4 hours, reaching a 90% decrease at 12 hours, which was fully reversed 72 hours after removal of the steroid. Budesonide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 42-46 24998372-4 2014 RESULTS: Treatment with formoterol and budesonide 72 h before and after RV14 infection reduced RV14 titers and cytokine concentrations, including interleukin (IL)-1beta, IL-6 and IL-8, in supernatants and viral RNA within cells. Budesonide 39-49 C-X-C motif chemokine ligand 8 Homo sapiens 179-183 23617551-10 2013 Inhaled budesonide significantly reduced LPS-induced IL-1beta, IL-6, IL-8 and TNF-alpha secretion, while inhaled formoterol had no such effect; however when combined, the inhibitory effect of budesonide was significantly increased by formoterol. Budesonide 8-18 C-X-C motif chemokine ligand 8 Homo sapiens 69-73 24164087-7 2014 Budesonide also reduced the concentrations of tumour necrosis factor-alpha, interleukin-1beta, interleukin-6 and interleukin-8 in bronchoalveolar lavage fluid, but increased interleukin-10 30 min after re-expansion (p < 0.05 for all measures). Budesonide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 113-126 24062615-7 2013 RESULTS: We have demonstrated that budesonide concentration-dependently (10(-10)-10(-7) M) inhibited IL-6, IL-8, MMP-1, and MMP-3 release by HFL-1 cells in response to IL-1beta plus TNF-alpha. Budesonide 35-45 C-X-C motif chemokine ligand 8 Homo sapiens 107-111 23573194-8 2013 Budesonide with Formoterol reduced IL-17A and RORgamma(t), while increased FOXP3 in cultured T-lymphocytes from mild-moderate asthma/persistent rhinitis, and reduced the IL-8 release mediated by IL-17A present in NW and Ss from mild-moderate asthma/persistent rhinitis in nasal and bronchial epithelial cells. Budesonide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 170-174 22546485-7 2012 RESULTS: Both long-acting beta(2) agonists, salmeterol and formoterol, and corticosteroids, fluticasone and budesonide, showed anti-inflammatory effects to a certain extent on H(2)O(2)-induced IL-8 and MMP-9 release in alveolar macrophages. Budesonide 108-118 C-X-C motif chemokine ligand 8 Homo sapiens 193-197 21828034-3 2012 We investigated whether interleukin (IL)-17A induces GC insensitivity in airway epithelium by studying its effects on responsiveness of tumour necrosis factor (TNF)-alpha-induced IL-8 production to budesonide in human bronchial epithelial 16HBE cells. Budesonide 198-208 C-X-C motif chemokine ligand 8 Homo sapiens 179-183 21828034-5 2012 We demonstrated that IL-17A-induced IL-8 production is normally sensitive to GCs, while IL-17A pre-treatment significantly reduced the sensitivity of TNF-alpha-induced IL-8 production to budesonide. Budesonide 187-197 C-X-C motif chemokine ligand 8 Homo sapiens 168-172 21646801-10 2011 Budesonide significantly inhibited R-837-induced IL-8 production in a concentration-dependent manner, and procaterol potentiated inhibition by budesonide although single-agent procaterol had no effect. Budesonide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 49-53 21300705-6 2011 Corticosteroid sensitivity was evaluated by the inhibition of tumor necrosis factor alpha (TNFalpha)-induced interleukin 8 (IL-8) production by budesonide. Budesonide 144-154 C-X-C motif chemokine ligand 8 Homo sapiens 109-122 21300705-6 2011 Corticosteroid sensitivity was evaluated by the inhibition of tumor necrosis factor alpha (TNFalpha)-induced interleukin 8 (IL-8) production by budesonide. Budesonide 144-154 C-X-C motif chemokine ligand 8 Homo sapiens 124-128 21395877-6 2011 RESULTS: Budesonide and dexamethasone produced a concentration-dependent inhibition of the LPS-induced IL-8 and TNF-alpha secretion with an E(max) about 90% of inhibition, which was reduced by approximately 30% in the presence of H(2)O(2) or CSE. Budesonide 9-19 C-X-C motif chemokine ligand 8 Homo sapiens 103-107 20729385-7 2010 Pretreatment with budesonide, a currently used inhaled corticosteroid, decreased LPS-induced expression of TNF-alpha, IL-6, and IL-8, and reduced LPS-induced neutrophilia by ~84%. Budesonide 18-28 C-X-C motif chemokine ligand 8 Homo sapiens 128-132 20388003-8 2010 Budesonide significantly attenuated the release and expression of IL-6 and IL-8 after exposure. Budesonide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 75-79 20307681-4 2010 Formoterol enhanced and budesonide inhibited IL-6, CXCL8 and CXCL1 release from LPS-stimulated neutrophils. Budesonide 24-34 C-X-C motif chemokine ligand 8 Homo sapiens 51-56 19926732-7 2010 Budesonide inhibited release of all three cytokines (EC(50) TNF-alpha: 1.2+/-0.4 nM; GM-CSF: 0.4+/-0.2 nM; CXCL8: 0.4+/-0.1 nM; n = 3-4). Budesonide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 107-112 20388003-11 2010 Budesonide reduced IL-6 and IL-8 production and enhanced expression of TLR2 in PBECs only in the presence of a proinflammatory stimulus. Budesonide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 28-32 14643170-5 2004 Pre-treatment with beclomethasone, budesonide or fluticasone reduced TNFalpha- and IL-1beta-stimulated IL-8 and RANTES release from HASMC in a dose dependent manner. Budesonide 35-45 C-X-C motif chemokine ligand 8 Homo sapiens 103-107 19439980-9 2009 RESULTS: Budesonide inhibited the release of TNF-alpha, IL-6 and IL-8 from sPLA(2)-stimulated macrophages in a concentration-dependent manner. Budesonide 9-19 C-X-C motif chemokine ligand 8 Homo sapiens 65-69 16428071-5 2006 Budesonide had a suppressive effect on both constitutive and LPS-induced IL-8 gene expression. Budesonide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 73-77 16266385-6 2005 A single dose of nasal budesonide caused a decrease in symptoms (P < 0.05) and nasal eosinophils (P < 0.05) with selective abrogation of IL-5 and IL-13 responses (P < 0.05), but a lack of effect on levels of eotaxin, RANTES, IL-8 and MCP-1. Budesonide 23-33 C-X-C motif chemokine ligand 8 Homo sapiens 234-238 16118056-4 2005 Addition of budesonide to the apical side of Caco-2 cells, decreased both IL-8 and ENA-78 mRNA levels in a dose dependent manner. Budesonide 12-22 C-X-C motif chemokine ligand 8 Homo sapiens 74-78 18415826-5 2008 Budesonide attenuated the IL-6 and IL-8 release, an inhibiting effect that was sustained, but not reinforced, by formoterol. Budesonide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 35-39 16448811-7 2006 The stimulatory effect of pyocyanin on the IL-1beta- or PDBu-stimulated IL-8 release was reduced in the presence of dexamethasone, budesonide, and fluticasone. Budesonide 131-141 C-X-C motif chemokine ligand 8 Homo sapiens 72-76 15946834-5 2005 The budesonide-treated subjects had significant reductions in IL-8 levels in the BAL after therapy (mean+/-sem, 1.53+/-0.72 at baseline vs. 0.70+/-0.48 ng/ml at 6 months, P=0.004) and a reduction in the mean percentages of neutrophils (17.16+/-2.67% vs. 13.25+/-2.28% P=0.002). Budesonide 4-14 C-X-C motif chemokine ligand 8 Homo sapiens 62-66 15946834-7 2005 In stable patients with COPD, treatment with inhaled budesonide for a period of 6 months has a positive effect on markers of lung inflammation, as assessed by reduction in percentage neutrophils and IL-8 concentration in BAL. Budesonide 53-63 C-X-C motif chemokine ligand 8 Homo sapiens 199-203 14643170-2 2004 This study was performed to investigate the effectiveness of the commonly used steroids beclomethasone, budesonide and fluticasone in downregulating HASMC production of RANTES and IL-8. Budesonide 104-114 C-X-C motif chemokine ligand 8 Homo sapiens 180-184 14643170-7 2004 TNFalpha- and IL-1beta-induced RANTES and IL-8 expression was reduced on the transcriptional level by pre-treatment with fluticasone and budesonide. Budesonide 137-147 C-X-C motif chemokine ligand 8 Homo sapiens 42-46 14643170-8 2004 The results suggest that the topical steroids fluticasone, budesonide and to a lesser extent beclomethasone may have beneficial effects on airway inflammation in asthma by reducing RANTES and IL-8-induced leukocyte infiltration into the airway wall. Budesonide 59-69 C-X-C motif chemokine ligand 8 Homo sapiens 192-196 14519149-5 2003 RESULTS: Following RV16-infection, a significant increase in IL-8 was observed in the placebo- and budesonide-treated asthmatics (P=0.033 and 0.037, respectively), whereas IL-1beta only increased in the two asthma groups combined (P=0.035). Budesonide 99-109 C-X-C motif chemokine ligand 8 Homo sapiens 61-65 11751182-5 2001 Budesonide treatment did not inhibit the functional response to ozone exposure, as determined by reduction in FEV(1) and increase in total symptom score, but it significantly blunted the increase in the percentage of sputum neutrophils and interleukin-8 concentrations in the supernatant (p < 0.05). Budesonide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 240-253 10805216-5 2000 IFN-gamma as well as the GCs, Dexamethasone and Budesonide, inhibited TNF-alpha induced IL-8 secretion in a dose-dependent manner. Budesonide 48-58 C-X-C motif chemokine ligand 8 Homo sapiens 88-92 11587995-5 2001 After budesonide treatment there was a significant decrease in the number of submucosal cells staining for total NF-kappaB, granulocyte macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF-alpha), accompanied by a significant decrease in mucosal eosinophils and expression of vascular cell adhesion molecule-1 (VCAM-1) in the endothelium and interleukin-8 (IL-8) in the epithelium. Budesonide 6-16 C-X-C motif chemokine ligand 8 Homo sapiens 372-385 11587995-5 2001 After budesonide treatment there was a significant decrease in the number of submucosal cells staining for total NF-kappaB, granulocyte macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF-alpha), accompanied by a significant decrease in mucosal eosinophils and expression of vascular cell adhesion molecule-1 (VCAM-1) in the endothelium and interleukin-8 (IL-8) in the epithelium. Budesonide 6-16 C-X-C motif chemokine ligand 8 Homo sapiens 387-391 11491146-4 2001 Budesonide (10(-8) M) reduced the amounts of both cytokines (GM-CSF and IL-8) by 40%. Budesonide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 72-76 11491146-9 2001 In conclusion, the combination of budesonide and formoterol reduces the secretion of granulocyte macrophage-colony stimulating factor to basal levels and counteracts the capacity of formoterol alone to induce interleukin-8 production, modulations which may facilitate improved asthma control. Budesonide 34-44 C-X-C motif chemokine ligand 8 Homo sapiens 209-222 11392584-3 2001 Budesonide inhibited FCS-induced IL-6 and IL-8 release in a dose-dependent manner. Budesonide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 42-46 11392584-5 2001 The IC25 of budesonide on IL-8 release was higher in nasal mucosa than in nasal polyps (145 pM vs. 4 pM). Budesonide 12-22 C-X-C motif chemokine ligand 8 Homo sapiens 26-30 11392584-8 2001 Budesonide and nedocromil sodium may exert their anti-inflammatory action in the respiratory mucosa by modulating the secretion of IL-6 and IL-8. Budesonide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 140-144 11392584-9 2001 The different effect of budesonide and nedocromil sodium on IL-6 and IL-8 release may be explained by differences in the mechanisms which regulate the upregulation of these cytokines in inflammatory responses. Budesonide 24-34 C-X-C motif chemokine ligand 8 Homo sapiens 69-73 11491146-0 2001 Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells. Budesonide 26-36 C-X-C motif chemokine ligand 8 Homo sapiens 51-55 34414894-6 2021 Budesonide reduced synthesis of interleukin 4 (IL-4), CXCL8, tumor necrosis factor alpha (TNFalpha) by NK and NKT-like cells, as well as production of interferon gamma (IFNgamma) by NK cells. Budesonide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 54-59 34414894-8 2021 The combination of azithromycin and budesonide had a more pronounced inhibitory effect on the production of IL-4 and CXCL8 by NK and NKT-like cells than the effect of these drugs alone. Budesonide 36-46 C-X-C motif chemokine ligand 8 Homo sapiens 117-122 10565558-6 1999 After budesonide treatment, the correlation between IL-8 and neutrophils remained, and a correlation between IL-8 and eosinophils emerged. Budesonide 6-16 C-X-C motif chemokine ligand 8 Homo sapiens 52-56 10565558-6 1999 After budesonide treatment, the correlation between IL-8 and neutrophils remained, and a correlation between IL-8 and eosinophils emerged. Budesonide 6-16 C-X-C motif chemokine ligand 8 Homo sapiens 109-113 10442524-10 1999 In conclusion, budesonide and fluticasone propionate, in concentrations that probably occur in the airway lining fluid during inhalational therapy, inhibited cytokine release from human lung epithelial cells (IL-6, IL-8) and alveolar macrophages (TNF-alpha, IL-6, IL-8). Budesonide 15-25 C-X-C motif chemokine ligand 8 Homo sapiens 215-219 10442524-10 1999 In conclusion, budesonide and fluticasone propionate, in concentrations that probably occur in the airway lining fluid during inhalational therapy, inhibited cytokine release from human lung epithelial cells (IL-6, IL-8) and alveolar macrophages (TNF-alpha, IL-6, IL-8). Budesonide 15-25 C-X-C motif chemokine ligand 8 Homo sapiens 264-268 9517606-9 1998 Budesonide decreased serum IL-8 from 9.2 +/- 3.7 to 6.2 +/- 2.1 pg/ml (p < 0.001). Budesonide 0-10 C-X-C motif chemokine ligand 8 Homo sapiens 27-31 34262692-11 2021 Interleukin (IL)-8, IL-10, IL-1alpha, and tissue inhibitor of metalloproteinase (TIMP)-1 concentrations were significantly increased in the culture medium of cells exposed to PM2.5, and budesonide significantly reduced the changes in IL-8, IL-1alpha, and TIMP-1. Budesonide 186-196 C-X-C motif chemokine ligand 8 Homo sapiens 0-18 34262692-11 2021 Interleukin (IL)-8, IL-10, IL-1alpha, and tissue inhibitor of metalloproteinase (TIMP)-1 concentrations were significantly increased in the culture medium of cells exposed to PM2.5, and budesonide significantly reduced the changes in IL-8, IL-1alpha, and TIMP-1. Budesonide 186-196 C-X-C motif chemokine ligand 8 Homo sapiens 234-238 34414894-9 2021 The combination of theophylline and budesonide suppressed synthesis of IL-4 and CXCL8 by NK and NKT-like cells, as well as the production of TNFalpha and IFNgamma by NK cells stronger than budesonide alone. Budesonide 36-46 C-X-C motif chemokine ligand 8 Homo sapiens 80-85 35072213-7 2022 The combination of azithromycin and budesonide suppressed inflammatory response by inhibition of IL-4, IL-5, IL-8, IL-13, IL-17A, IL-33, thymic stromal lymphopoietin (TSLP), macrophage migration inhibitory factor (MIF) release from PBMCs and by reduction of the percentage of IL-4-, IL-8-, interferon gamma- and tumor necrosis factor a-expressing CD4+ and CD8+ T cells. Budesonide 36-46 C-X-C motif chemokine ligand 8 Homo sapiens 109-113 35072213-8 2022 The inhibitory effect of azithromycin combined with budesonide on IL-4, IL-5, IL-8, IL-17A, TSLP production by PBMCs, as well as IL-4 and IL-8 production by T helper cells and cytotoxic T lymphocytes was significantly greater than the effect of budesonide alone. Budesonide 52-62 C-X-C motif chemokine ligand 8 Homo sapiens 78-82